Skip to main content
    B

    BioLife Solutions Inc (BLFS)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $38.61
    +0.00 (+0.00%)

    Market Cap: $1.89B

    Last updated: Oct 14, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    -36.67%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.07
    Range$0.07 - $0.07
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.04+75.0%
    60d ago$0.070.0%
    30d ago$0.070.0%
    7d ago$0.070.0%
    Current$0.07
    Revenue Consensus
    $29M
    Range$29M - $30M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.10
    Range$0.10 - $0.10
    1 analysts
    Revenue Consensus
    $32M
    Range$32M - $33M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.10---
    Sep 26EST
    		-$0.07---
    Jun 26
    Reported Aug 6
    		$0.04$-0.01+500.00%Beat+112.1%
    Mar 26
    Reported May 7
    		$0.04$0.02+100.00%Beat+0.0%
    Dec 25
    Reported Feb 26
    		$0.04$-0.02+300.00%Beat+350.0%
    Sep 25
    Reported Nov 6
    		$0.04$-0.01+453.98%Beat+300.0%
    Jun 25
    Reported Aug 7
    		$-0.33$-0.02-1550.00%Miss-560.0%
    Mar 25
    Reported May 8
    		$0.04$-0.04+200.00%Beat+117.4%
    Dec 24
    Reported Mar 3
    		$-0.02N/A+71.78%Beat+92.4%
    Sep 24
    Reported Nov 12
    		$-0.02N/A+60.00%Beat+94.1%
    Jun 24
    Reported Aug 8
    		$-0.05$-0.09+44.44%Beat+79.2%
    Mar 24
    Reported May 9
    		$-0.23$-0.28+17.86%Beat+14.8%
    Dec 23
    Reported Feb 29
    		$-0.21$-0.27+22.22%Beat+81.7%
    Sep 23
    Reported Nov 9
    		$-0.34$-0.28-21.43%Miss-126.7%
    Jun 23
    Reported Aug 8
    		$-0.24$-0.18-33.33%Miss-84.6%
    Mar 23
    Reported May 10
    		$-0.27$-0.16-68.75%Miss-42.1%
    Dec 22
    Reported Mar 16
    		$-1.15$-0.17-576.47%Miss-210.8%
    Sep 22
    Reported Nov 9
    		$-0.15$-0.10-50.00%Miss+21.1%
    Jun 22
    Reported Aug 9
    		$-0.13$-0.15+13.33%Beat-8.3%
    Mar 22
    Reported May 9
    		$-0.19$-0.17-11.76%Miss-2000.0%
    Dec 21
    Reported Feb 28
    		$-0.37$-0.17-117.65%Miss-516.7%
    Sep 21
    Reported Nov 11
    		$-0.19$-0.09-111.11%Miss-850.0%
    Jun 21
    Reported Aug 12
    		$-0.12$0.03-500.00%Miss-1100.0%
    Mar 21
    Reported May 13
    		$0.01N/A+125.00%Beat-83.3%
    Dec 20
    Reported Mar 22
    		$-0.06$-0.02-200.00%Miss-400.0%
    Sep 20
    Reported Nov 5
    		$-0.02$-0.01-100.00%Miss-300.0%
    Jun 20
    Reported Aug 6
    		$-0.01N/A+75.00%Beat-125.0%
    Mar 20
    Reported May 14
    		$0.06$0.02+200.00%Beat+20.0%
    Dec 19
    Reported Mar 11
    		$0.02$-0.02+200.00%Beat-50.0%
    Sep 19
    Reported Nov 12
    		$0.01$0.02-50.00%Miss-85.7%
    Jun 19
    Reported Aug 8
    		$0.04$0.05-20.00%Miss-33.3%
    Mar 19
    Reported May 9
    		$0.05$0.06-16.67%Miss+600.0%
    Dec 18
    Reported Mar 14
    		$0.04$0.05-20.00%Miss+180.0%
    Sep 18
    Reported Nov 8
    		$0.07$0.07+0.00%Beat+450.0%
    Jun 18
    Reported Aug 9
    		$0.06$0.05+20.00%Beat+250.0%
    Mar 18
    Reported May 10
    		$-0.01$0.02-150.00%Miss+80.0%
    Dec 17
    Reported Mar 8
    		$-0.05$-0.04-25.00%Miss+80.8%
    Sep 17
    Reported Nov 9
    		$-0.02N/A+60.00%Beat-
    Jun 17
    Reported Aug 10
    		$-0.04$-0.04+0.00%Beat-
    Mar 17
    Reported May 11
    		$-0.05$-0.05+0.00%Beat-
    Dec 16
    Reported Mar 9
    		$-0.26$-0.07-271.43%Miss-

    Key Metrics

    Valuation
    P/E Ratio241.31EV/EBITDA248.67x
    Price/FCF232.73xFCF Yield0.43%
    Profitability
    Profit Margin54.30%Operating Margin5.96%
    ROE12.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio9.69xQuick Ratio7.14x
    Trading Statistics
    Beta1.82Avg Volume1.30M
    52-Week High$39.7652-Week Low$17.86

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$38.30
    SMA 20$38.19
    SMA 50$36.68
    SMA 200$27.09
    EMA 10$38.44
    EMA 20$37.99
    EMA 50$36.10
    EMA 200$29.57

    MACD

    Line: 0.70Signal: 0.79Hist: -0.09

    ADX

    ADX: 34.8+DI: 26.4-DI: 15.9

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down4.0
    PSAR$39.25

    Bollinger Bands

    Upper Band$39.79
    Lower Band$36.59
    %B Position837%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    60.6

    Momentum Oscillators

    Stoch %K62.4
    Stoch %D62.6
    Williams %R-37.6
    ROC (10d)-0.6%
    Momentum-0.24
    CCI (20d)48.4
    MFI (14d)60.6

    Volatility Measures

    ATR (14d)$0.68(1.7%)
    StdDev (20d)0.80
    Hist Vol28.6%(Moderate)

    Volume Flow

    VWAP$38.61
    OBV22.9M
    AD Line3.9M
    CMF (20d)0.236

    Volume Metrics

    Avg Vol (20d)904.2K
    Vol RatioN/A
    VWMA (20d)$38.01

    Pivot Points

    R3$38.61
    R2$38.61
    R1$38.61
    Pivot Point$38.61
    S1$38.61
    S2$38.61
    S3$38.61

    Advanced Oscillators

    TSI21.73
    Ultimate OscN/A
    KST59.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$28.47M$27.50M$18.79M$28.07M$23.44M$22.05M$15.11M$21.39M$19.71M$18.43M$-22,497,000$23.57M
    Cost of Revenue$10.18M$10.00M$6.81M$10.15M$8.20M$7.25M$4.45M$7.40M$6.51M$6.19M$-26,757,000$11.58M
    Gross Profit$18.29M$17.50M$11.98M$17.92M$15.23M$14.80M$10.66M$13.99M$13.21M$12.24M$4.26M$11.99M
    Operating Expenses$16.59M$17.47M$10.63M$18.01M$31.36M$15.30M$10.12M$14.41M$14.51M$15.54M$-18,243,000$27.47M
    R&D$2.96M$2.65M$-66,000$2.71M$1.97M$1.44M$-1,246,000$1.89M$2.03M$2.08M$-6,169,000$3.74M
    SG&A$10.69M$12.21M$10.55M$12.07M$11.23M$11.35M$11.59M$9.33M$9.32M$10.40M$3.60M$10.81M
    Operating Income$1.70M$27,000$1.35M$-89,000$-16,126,000$-499,000$542,000$-418,000$-1,306,000$-3,295,000$22.50M$-15,475,000
    Interest Income$994,000$1.04M$833,000$508,000$684,000$683,000$-71,000$-230,000$-4,399,000$-140,000$-159,000$-449,000
    Interest Expense$0$0$0$0$0$0$73,000$133,000$4.25M$0$0$214,000
    Income Before Tax$2.75M$1.25M$3.36M$703,000$-15,195,000$285,000$469,000$-551,000$-5,559,000$-3,182,000$22.61M$-15,689,000
    Income Tax Expense$-42,351,000$62,000$-173,000$82,000$126,000$14,000$24,000$-80,000$1,000$17,000$-273,000$115,000
    Net Income$45.10M$1.19M$11.07M$621,000$-15,838,000$-448,000$12.46M$-1,703,000$-20,719,000$-10,221,000$-14,957,000$-29,132,000
    EBITDA$2.49M$784,000$2.91M$1.30M$-14,697,000$881,000$2.18M$1.91M$1.07M$-946,000$24.93M$-12,272,000
    EBIT$1.76M$207,000$2.53M$195,000$-15,879,000$-398,000$540,000$-321,000$-1,160,000$-3,042,000$22.77M$-15,240,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BLFS

    Government Contracts

    Gov Obligations (TTM)
    $23680
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Top agency: Department of Health and Human Services at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75N90025P00614Department of Health and Human ServicesNational Institutes of Health$23680Aug 6, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    BIOLIFE SOLUTIONS INC SEC Filing (Oct 13, 2026)

    This article announces an SEC filing for BioLife Solutions Inc. (BLFS) on October 13, 2026, specifically a Notice of Effectiveness (EFFECT) with a neutral filing impact and sentiment. The filing indicates...

    Stock Titan•10/13/26•Neutral

    Form EFFECT BIOLIFE SOLUTIONS INC

    This article announces the effectiveness of a Form EFFECT filing by BIOLIFE SOLUTIONS INC with the SEC. The filing has an effectiveness date of October 9, 2026...

    StreetInsider•10/13/26•Neutral

    Form 4 BIOLIFE SOLUTIONS INC For: 8 October By Investing.com

    This article reports on a Form 4 filing for BioLife Solutions Inc. for October 8th. Form 4 filings are legally required documents submitted to the U.S. Securities and Exchange Commission (SEC) by company insiders...

    Investing.com Nigeria•10/9/26•Neutral

    Stock awards vested at about 200% of grants for BioLife Solutions (BLFS) CEO before merger dispositions.

    BioLife Solutions Inc. CEO Roderick de Greef reported significant stock transactions on October 6, 2026, including the acquisition of 225,670 and 237,460 restricted shares that vested at approximately 200% of the granted...

    Stock Titan•10/9/26•Neutral

    Form 4 BIOLIFE SOLUTIONS INC For: 8 October By Investing.com

    This article from Investing.com reports on the filing of a Form 4 for BIOLIFE SOLUTIONS INC, specifically for October 8th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC)...

    Investing.com Nigeria•10/8/26•Neutral

    BLFS Valuation and Fair Value

    P/E
    241.3x
    Forward P/E
    238.1x
    EV/EBITDA
    248.7x
    P/FCF
    232.7x
    PEG
    65.4x
    P/B
    4.5x
    See GNG's fair value

    BLFS Profitability: Margins, ROIC and FCF

    Gross margin
    63.9%
    Operating margin
    6.0%
    Net margin
    54.3%
    ROE
    12.8%
    FCF margin
    7.9%
    FCF yield
    0.4%

    BLFS Competitors

    CompanyTicker
    LeMaitre Vascular IncLMAT
    Schrodinger IncSDGR
    Vera Therapeutics IncVERA
    UroGen Pharma LtdURGN
    Inspire Medical Systems IncINSP
    Surgery Partners IncSGRY
    Recursion Pharmaceuticals IncRXRX
    Mineralys Therapeutics, Inc. Common StockMLYS

    Sector: Healthcare

    BLFS Analyst Ratings

    Consensus
    Hold
    Analysts
    9
    Strong Buy
    0
    Buy
    1
    Hold
    8
    Sell
    0
    Strong Sell
    0

    BLFS Bull Case vs Bear Case

    Bull case

    • BLFS has a 54.3% net profit margin.
    • BLFS beat EPS estimates in 87.5% of its last 8 reported quarters.
    • BLFS grew quarterly revenue 21.5% year over year.

    Bear case

    • BLFS trades at 241.3x trailing earnings.

    BLFS Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    17.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About BLFS

    Does BLFS pay dividends?

    BioLife Solutions Inc (BLFS) does not currently pay a regular dividend.

    What is BLFS's P/E ratio?

    BioLife Solutions Inc has a price-to-earnings (P/E) ratio of 241.31.

    What is BLFS's market cap?

    BioLife Solutions Inc (BLFS) has a market capitalization of $1.89B with a current stock price of $38.61.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In